Cargando…
Difluprednate for the prevention of ocular inflammation postsurgery: an update
PURPOSE: To review the most recent published data regarding the novel potent steroid, difluprednate ophthalmic emulsion, 0.05%. METHODS: A comprehensive search of recent published literature including difluprednate was performed. Clinical studies relevant to the characteristics and clinical efficacy...
Autor principal: | Donnenfeld, Eric D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130919/ https://www.ncbi.nlm.nih.gov/pubmed/21750615 http://dx.doi.org/10.2147/OPTH.S6541 |
Ejemplares similares
-
The role of difluprednate ophthalmic emulsion in clinical practice
por: Jamal, Karim N, et al.
Publicado: (2009) -
Topical difluprednate for the treatment of Harada’s disease
por: Onishi, Spencer M, et al.
Publicado: (2015) -
Difluprednate ophthalmic emulsion 0.05% (Durezol(®)) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Smith, Stephen, et al.
Publicado: (2010) -
Pain: Persistent postsurgery and bone cancer-related pain
por: Feller, Liviu, et al.
Publicado: (2019) -
Topical difluprednate for the treatment of retinal vasculitis associated with birdshot chorioretinitis
por: Wang, Jay C., et al.
Publicado: (2016)